Ryvu Therapeutics stock reports H1 loss improvement after index exit

Ryvu Therapeutics stock is framed by a sharply smaller adjusted net loss of PLN 25.5 million in the first half of 2026, versus PLN 57.1 million in the same period of 2025, according to Strefa Inwestorow on September 17, 2026. The improvement came alongside lower operating costs and a more concentrated oncology pipeline.

Loss narrows as costs fall

Ryvu reported PLN 38.7 million in operating revenue for H1 2026, compared with PLN 42.4 million in H1 2025. Operating costs excluding incentive-program expenses and the valuation of NodThera interests fell to PLN 67.6 million from PLN 95.5 million, while EBITDA loss narrowed to PLN 24.7 million from PLN 60.6 million, according to Strefa Inwestorow.

The key comparison is operational rather than top-line growth: revenue declined by PLN 3.7 million year over year, while the adjusted net loss improved by PLN 31.6 million. For investors, the cost base and funding runway therefore carry more weight than revenue expansion alone.

Pipeline milestones support the strategy

Ryvu said its romacyclib program entered an expanded RIVER-81 cohort after the first patient was dosed on August 26, 2026. The company also launched Keelira on August 18 as a clinical-development services business for biotechnology and pharmaceutical companies, a move reported by ClinLab International on September 21, 2026.

Funding remains central to the model. Ryvu reported cash, equivalents, bonds and investment funds of PLN 62.1 million as of September 10, 2026, alongside grant funding secured under signed agreements. The planned service business and grant pipeline could diversify financing while the company advances its own oncology programs.

Index change adds market pressure

MarketScreener reported on September 20, 2026, that Ryvu was dropped from the S&P Global BMI Index. The index change is a separate market-structure headwind, while the half-year figures show that cost discipline is improving reported profitability.

Warsaw quote remains below yearly high

Ryvu was trading at PLN 15.78 on the Warsaw Stock Exchange on September 30, 2026 at 4:45 p.m. CEST, down 0.75 percent from PLN 15.90. The 52-week range was PLN 13.64 to PLN 31.90, and market capitalization stood at PLN 364.8 million on September 30, 2026.